Journal: The Journal of biological chemistry

Article Title: Chimeric erythropoietin-interferon gamma receptors reveal differences in functional architecture of intracellular domains for signal transduction.

doi: 10.1074/jbc.272.8.4993

Figure Lengend Snippet: FIG. 7. Phosphorylation of Jak1 and Jak2 kinases. Untreated cells or cells treated with Hu-IFN-g or Epo were lysed and immunoprecipi- tated (I.P.) with monoclonal anti-phosphotyrosine antibodies (anti-P-Tyr panels), polyclonal anti-Jak1 antibodies (anti-Jak1 panels) or anti-Jak2 antibodies (anti-Jak2 panels) as described under “Materials and Methods.” The cell lines are indicated on the figure and are defined in the legend to Fig. 1. Immunoprecipitates were resolved on SDS-PAGE, transferred to PVDF membranes and the blots probed with anti-Jak1 or anti-Jak2 antibodies as noted under the respective horizontal panels.

Article Snippet: Rabbit anti-Jak2 antibody (catalogue no. SC-294) and rabbit anti-Stat5 antibody (catalogue no. SC-835) were from Santa Cruz Biotechnology.

Techniques: Phospho-proteomics, SDS Page

Journal: The Journal of biological chemistry

Article Title: Chimeric erythropoietin-interferon gamma receptors reveal differences in functional architecture of intracellular domains for signal transduction.

doi: 10.1074/jbc.272.8.4993

Figure Lengend Snippet: FIG. 8. Schematic representation of receptor complexes. A represents the IFN-gR1 homodimer bound to IFN-g. The cytoplasmic domains of the two chains are too far apart to permit transactivation of the two Jak1 kinases. B represents the active heteromeric IFN-g receptor com- plex with two IFN-gR1 and two IFN-gR2 subunits per complex. The IFN-g ho- modimer binds to two IFN-gR1 chains, followed by its interaction with two IFN- gR2 chains. The associated Jak2 and Jak1 kinases activate one another by transphosphorylation, with subsequent phosphorylation and dimerization of Stat1a. C depicts the EpoR/gR1 ho- modimer, which, unlike the IFN-gR1 ho- modimer, permits transactivation of the two Jak1 molecules. D illustrates the structure of the heterodimer of EpoR/gR1 and EpoR/gR2, which is the putative ac- tive receptor complex.

Article Snippet: Rabbit anti-Jak2 antibody (catalogue no. SC-294) and rabbit anti-Stat5 antibody (catalogue no. SC-835) were from Santa Cruz Biotechnology.

Techniques: Phospho-proteomics

Journal: bioRxiv

Article Title: Arginine-GlcNAcylation of death domain and NleB/SseK proteins is crucial for bacteria pathogenesis by regulating host cell death

doi: 10.1101/746883

Figure Lengend Snippet: Multiple sequence alignment of 12 death domains (DDs) from human proteins containing death domain. The red asterisk indicates the conserved arginine site among different DDs, which could be GlcNAcylated by NleB/SseKs. (B) Site distribution of amino acids in 12 death receptor domains containing conserved arginine by Weblogo. (C) Phylogenetic tree of the 12 DDs constructed on the basis of sequence similarity. (D-G) Identification of the physiological substrates of arginine GlcNAc transferase NleB/SseKs during bacterial infection of mammalian cells. 293T cells transfected with pCS2-1Flag-TNFR1 DD, pCS2-1Flag-TRADD DD, pCS2-1Flag-FADD, and pCS2-1Flag-RIPK1 DD were infected with the indicated modified EPEC strains or Salmonella strains. After infection, cells were lysed, and proteins were immunoprecipitated with FLAG M2 beads. Samples were loaded onto SDS-PAGE gels and were immunoblotted with anti-Flag, anti-Arg-GlcNAc, and a loading control anti-tubulin. Data in Fig (D - G) are from at least three independent experiments.

Article Snippet: The anti-GlcNAc arginine antibody (ab195033, Abcam) was described previously( ).

Techniques: Sequencing, Construct, Infection, Transfection, Modification, Immunoprecipitation, SDS Page

Journal: bioRxiv

Article Title: Arginine-GlcNAcylation of death domain and NleB/SseK proteins is crucial for bacteria pathogenesis by regulating host cell death

doi: 10.1101/746883

Figure Lengend Snippet: ( A ) Multiple sequence alignment of 37 death domains (DDs) from human death domain-containing proteins. ( B ) Identification of the physiological substrates of arginine GlcNAc transferase NleB/SseKs during EPEC infection of mammalian cells. 293T cells transfected with pCS2-1Flag-TRADD DD, pCS2-1Flag-FADD DD, and pCS2-1Flag-RIPK1 DD were infected with the indicated modified EPEC strains. After infection, cells were lysed, and proteins were immunoprecipitated with FLAG M2 beads. Samples were loaded onto SDS-PAGE gels and were immunoblotted with anti-Flag, anti-Arg-GlcNAc, and a loading control anti-tubulin. Blot data were derived from at least three independent experiments.

Article Snippet: The anti-GlcNAc arginine antibody (ab195033, Abcam) was described previously( ).

Techniques: Sequencing, Infection, Transfection, Modification, Immunoprecipitation, SDS Page, Derivative Assay

Journal: bioRxiv

Article Title: Arginine-GlcNAcylation of death domain and NleB/SseK proteins is crucial for bacteria pathogenesis by regulating host cell death

doi: 10.1101/746883

Figure Lengend Snippet: An arginine point mutation screen of hTRADD to investigate its ability to be GlcNAcylated by SseK1. 293T cells were transfected with the indicated plasmid combinations. The samples of anti-Flag immunoprecipitates (Flag IP) and total cell lysates (Input) were immunoblotted with corresponding antibodies. Anti-tubulin was used as a loading control. (B) Electrospray ionization mass spectrometry (ESI-MS) determination of the total mass of the site-directed TRADD mutants purified from bacteria. GST-TRADD DD, GST-TRADD DD (R235A), GST-TRADD DD (R245A), and GST-TRADD DD (R235A/R245A) were expressed alone (upper panel) or co-expressed with His-SseK1 (lower panel) in E. coli BL21 (DE3) strain. The resulting mass spectra were shown. The resulting mass spectra were shown. The black bar and red bar denote unmodified and GlcNAcylated TRADD DD, respectively. (C) The percentage of site-directed TRADD mutants GlcNAcylated by SseK1. (D) HCD analysis of the peptides of TRADD DD R245 GlcNAcylated by SseK1 in bacteria. The fragmentation patterns of the generated b and y ions were shown along the peptide sequence on the top of the spectrum. (E) Modification of TRADD and TRADD variants by SseK1 upon S. Typhimurine infection. 293T cells was transfected with plasmids carrying TRADD and the site-directed TRADD mutants, and then infected with the indicated Salmonella strains. After 15-hour infection, cells were lysed and proteins were immunoprecipitated with FLAG M2 beads. Samples were loaded onto SDS-PAGE gels, followed by immunoblots with anti-Flag and anti-Arg-GlcNAc antibodies. (F) Identification of the site of TNFR1 GlcNAcylated by SseK3 in bacteria. (G) Summary of ESI-MS determination of the total mass of TNFR1 and its point mutants co-expressed with SseK3 in bacteria. Data in Fig (A, E, and F) are from at least three independent experiments.

Article Snippet: The anti-GlcNAc arginine antibody (ab195033, Abcam) was described previously( ).

Techniques: Mutagenesis, Transfection, Plasmid Preparation, Mass Spectrometry, Purification, Generated, Sequencing, Modification, Infection, Immunoprecipitation, SDS Page, Western Blot

Journal: bioRxiv

Article Title: Arginine-GlcNAcylation of death domain and NleB/SseK proteins is crucial for bacteria pathogenesis by regulating host cell death

doi: 10.1101/746883

Figure Lengend Snippet: (A) Ectopic expression of NleB/SseKs effectors showed the related subcellular localization and modification pattern in transfected HeLa cells. GFP-NleB, GFP-SseK1, GFP-SseK2, and GFP-SseK3 were expressed ectopically in HeLa cells. In HeLa cells, green indicated immunofluorescence staining of GFP and arginine-GlcNAcylated proteins. Blue indicated DAPI staining of nuclei, and red indicated GM130 staining of the Golgi structure. (B) Analysis of NleB/SseKs auto-arginine-GlcNAcylation by Western blot. Recombinant purified NleB/SseKs and their enzymatic mutants were analyzed on SDS-PAGE gels, followed by immunoblotting with anti-Arg-GlcNAc. (C) ESI-MS analysis determination of the total mass of the NleB/SseKs purified from bacteria. The black bar denotes unmodified protein. For NleB and SseK3, the red bar denotes GlcNAcylated form with 203-Da increase, while for SseK1, the red bar denotes GlcNAcylated (203 Da) and acetylated (42 Da) form with 245-Da increase. (D) Arginine-GlcNAcylation percentage of NleB/SseKs. (E) Summary of ESI-MS determination of the total mass of NleB/SseKs. Data in (A and B) are representative from at least three independent experiments.

Article Snippet: The anti-GlcNAc arginine antibody (ab195033, Abcam) was described previously( ).

Techniques: Expressing, Modification, Transfection, Immunofluorescence, Staining, Western Blot, Recombinant, Purification, SDS Page

Journal: bioRxiv

Article Title: Arginine-GlcNAcylation of death domain and NleB/SseK proteins is crucial for bacteria pathogenesis by regulating host cell death

doi: 10.1101/746883

Figure Lengend Snippet: Effects of the auto-arginine-GlcNAcylation of NleB on enzyme activity towards death domain protein. The coupled anti-Arg-GlcNAc beads were incubated with 50 μg of purified NleB for enrichment with auto-arginine-glycosylated NleB. Beads enriched with auto-arginine-glycosylated proteins were used in vitro glycosylation assay. Samples were loaded onto SDS-PAGE gels and were immunoblotted with anti-Flag and anti-Arg-GlcNAc. (B) Mass spectrometry analysis of 203-Da increase in the total molecular weight of the auto-arginine-GlcNAcylation site-directed mutant proteins. (C) Effects of the modification site mutation of NleB/SseKs. 293T cells were transfected with the indicated plasmids. After 24-hour transfection, cells were lysed, and proteins were immunoprecipitated with α-FLAG conjugated beads. Samples were loaded onto SDS-PAGE gels, followed by immunoblot with anti-Flag, anti-Arg-GlcNAc, and a loading control anti-tubulin. (D-F) Effects of the auto-arginine-GlcNAcylation on cell death inhibition of NleB and SseKs. HeLa cells infected with the indicated EPEC strains and Salmonella strains were stimulated with TNF-α and TRAIL. Cell viability was determined by measuring ATP levels. Black bars or white bars denoted unstimulated or stimulated, respectively. Data in (A) and (C-F) are representative from at least three independent experiments.

Article Snippet: The anti-GlcNAc arginine antibody (ab195033, Abcam) was described previously( ).

Techniques: Activity Assay, Incubation, Purification, In Vitro, SDS Page, Mass Spectrometry, Molecular Weight, Mutagenesis, Modification, Transfection, Immunoprecipitation, Western Blot, Inhibition, Infection

Journal: NPJ breast cancer

Article Title: The human intermediate prolactin receptor is a mammary proto-oncogene.

doi: 10.1038/s41523-021-00243-7

Figure Lengend Snippet: Fig. 5 hPRLrL + I heterodimer signal transduction. MCF10AT transfectants were PRL (250 ng/mL) stimulated for 0, 15, and 30 min, and phospho-IB was utilized to assess the activation status of a, b Jak2/Stat5a and c, d Mek/Erk. Band intensities were quantified using densitometry. Significance was determined by comparing each condition to the MCF10AT-EV negative control for each respective time point. *p < 0.05, n = 3.

Article Snippet: Antibodies used for these studies were obtained from the following sources at the indicated titer: hPRLr ECD (35–9200, Invitrogen, 1:1000), pY-Stat5a (9359S, Cell Signaling, 1:1000), Stat5a (sc-1081, Santa Cruz Biotechnology, 1:1000), pY-Jak2 (3776S, Cell Signaling, 1:500), Jak2 (3230S, Cell Signaling, 1:500), pp44/42 (9101S, Cell Signaling, 1:1000), p44/42 (9102S, Cell Signaling, 1:1000), pS-Mek (9121S, Cell Signaling, 1:1000), Mek (9122S, Cell Signaling, 1:1000), KRAS (14412S, Cell Signaling, 1:1000), hPRLrI (New England Peptide, 1:5000), pS349-hPRLr (Serge Y. Fuchs, M.D., Ph.D., University of Pennsylvania, 1:100), Vinculin (MCA465GA, Bio-Rad, 1:1000).

Techniques: Transduction, Activation Assay, Negative Control

Journal: Frontiers in immunology

Article Title: PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.

doi: 10.3389/fimmu.2021.762989

Figure Lengend Snippet: FIGURE 4 | Pamiparib treatment induces PD-L1 expression via JAK2/STAT3 pathway. (A) Cells were pretreated with pamiparib (100 mM, 12h) and PD-L1 expression was assessed by immunoblotting after treatment with the concentrations (20 mM) of AG490 for 24h. (B) Cells were pretreated with pamiparib (100 mM, 12h) and PD-L1 expression was assessed by protein blotting after treatment with stattic (20 mM) for 24h. (C) Protein expression of phospho-JAK2 (p-JAK2), JAK2, and PD-L1 in SW1990 cells after being treated with pamiparib (100 mM) for the indicated times. (D) Protein expression of phospho-STAT3(p-STAT3), STAT3 and PD-L1 in SW1990 cells after being treated with pamiparib (100 mM) for the indicated times. GAPDH was used as a loading control. (E) IHC staining of p-STAT3 of nude mouse xenograft tumors in control group and treated with pamiparib group. Scale bar, 100 mm. (F) IHC staining score showed the expression of p-STAT3 was significantly upregulated in nude mice pamiparib treated group. Data are mean ± SD; n = 3 samples per group. The IHC results were analyzed by Pearson c2 test. *P < 0.05.

Article Snippet: The primary antibodies are PD-L1 (CST #13684, Cell Signaling Technology), PD-L1 (17952- 1-AP, Santa Cruz), STAT3 (CST #9139, Cell Signaling Technology), phosphorylated STAT3 (CST #9145, Cell Signaling Technology), JAK2 (17670-1-AP, Proteintech), phosphorylated JAK2 (CST #4406, Cell Signaling Technology), AKT (10176-2-AP, Proteintech), phosphorylated AKT (66444-1-Ig, Proteintech), ERK (CST #4696, Cell Signaling Technology), phosphorylated ERK (CST #3510, Cell Signaling Technology), PARP-1 (sc-8007, Santa Cruz), and GAPDH (60004-1-Ig, Proteintech).

Techniques: Expressing, Western Blot, Control, Immunohistochemistry

Journal: Frontiers in immunology

Article Title: PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.

doi: 10.3389/fimmu.2021.762989

Figure Lengend Snippet: FIGURE 8 | Diagram summarizing that pamiparib treatment induces PD-L1 expression mainly via JAK2/STAT3 in pancreatic cancer (details provided in the Discussion section).

Article Snippet: The primary antibodies are PD-L1 (CST #13684, Cell Signaling Technology), PD-L1 (17952- 1-AP, Santa Cruz), STAT3 (CST #9139, Cell Signaling Technology), phosphorylated STAT3 (CST #9145, Cell Signaling Technology), JAK2 (17670-1-AP, Proteintech), phosphorylated JAK2 (CST #4406, Cell Signaling Technology), AKT (10176-2-AP, Proteintech), phosphorylated AKT (66444-1-Ig, Proteintech), ERK (CST #4696, Cell Signaling Technology), phosphorylated ERK (CST #3510, Cell Signaling Technology), PARP-1 (sc-8007, Santa Cruz), and GAPDH (60004-1-Ig, Proteintech).

Techniques: Expressing

Journal: JNCI Journal of the National Cancer Institute

Article Title: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

doi: 10.1093/jnci/djt006

Figure Lengend Snippet: Evidence of Abelson helper integration site 1 (Ahi-1)–Janus kinase 2 (Jak2) and Ahi-1-BCR-ABL interactions in BCR-ABL – and Jak2 -transduced cells coexpressing Ahi-1 and its mutants. A) Schematic of functional domains of full-length and mutant (N-ter∆) Ahi-1. Vectors were transduced into BaF3 cells and BCR-ABL –inducible cells, and increased protein expression levels of full-length and mutant Ahi-1 were detected by Western blotting. B) Ahi-1 ( left panel ) or Jak2 ( right panel ) were immunoprecipitated from lysates of the same transduced cells and then electrophoresed and probed with specific antibodies, as indicated. C) Human influenza hemagglutinin (HA)–tagged SH3 ∆ or SH3WD40 ∆ mutants were transfected into 293T cells with or without a Jak2 vector, immunoprecipitated with antibodies to either HA or Jak2, electrophoresed, and probed using Jak2 or Ahi-1 antibodies ( left panel ). The right panel shows that these two mutants were coexpressed with BCR-ABL , immunoprecipitated with an anti-HA antibody, and probed with a c-ABL antibody. A schematic of the functional domains of full-length Ahi-1 and its SH3 ∆ and SH3WD40 ∆ mutants is below the right panel. IP = immunoprecipitation; WB = Western blotting.

Article Snippet: The antibodies in this study included a rabbit polyclonal N-terminal AHI-1 antibody and an antimouse Ahi-1 mouse monoclonal antibody (1:1000 dilution) (C-mAhi-1 M5, Applied Biological Materials Inc Vancouver, BC, Canada), an antimouse ABL mouse monoclonal antibody (1:1000 dilution) (8E9; BD Biosciences), an antimouse JAK2 rabbit monoclonal antibody (1:1000 dilution) (Cell signaling Technology, MA), a rabbit polyclonal anti-JAK2 agarose conjugated antibody (Santa Cruz Biotechnology), anti-phospho-JAK2 rabbit polyclonal antibodies (1:1000 dilution) (Cell Signaling and Epitomics Inc, Burlingame, CA), an antihuman STAT5 rabbit polyclonal antibody (1:1000 dilution) (Millipore, Billeria, MA), an anti-phospho-STAT5 rabbit monoclonal antibody (1:1000 dilution) (Cell Signaling), an antihuman phospho-CRKL rabbit polyclonal antibody (1:2000 dilution) (Cell Signaling), an antihuman CRKL rabbit polyclonal antibody (1:1000 dilution) (Santa Cruz Biotechonolgy), an antiphosphotyrosine mouse monoclonal antibody (4G10) (1:2000 dilution) (Millipore, Billerica, MA), an anti-phospho-AKT rabbit polyclonal antibody (1:1000 dilution) (Cell Signaling), an antimouse Akt rabbit polyclonal antibody (1:1000 dilution) (Cell Signaling), an antihuman phospho-ERK rabbit polyclonal antibody (1:1000 dilution), an antirat ERK rabbit polyclonal (1:1000 dilution), an antimouse GAPDH mouse monoclonal antibody (1:2000 dilution) (Sigma Aldrich), an antiactin mouse monoclonal antibody (1:1000 dilution) (Sigma Aldrich), and an anti-HA mouse monoclonal antibody (1:1000 dilution) (Applied Biological Materials Inc).

Techniques: Functional Assay, Mutagenesis, Expressing, Western Blot, Immunoprecipitation, Transfection, Plasmid Preparation

Journal: JNCI Journal of the National Cancer Institute

Article Title: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

doi: 10.1093/jnci/djt006

Figure Lengend Snippet: Effect of imatinib (IM) on induction of apoptosis and inhibition of colony formation in BCR-ABL –transduced cells coexpressing Abelson helper integration site 1 ( Ahi-1 ) mutants and combined treatment with IM and a Janus kinase 2 (JAK2) inhibitor on inhibition of growth of AHI-1 –overexpressing and IM-resistant cells. A) BCR-ABL –transduced cells coexpressing full-length Ahi-1 and its mutants were cultured with IM, and the treated cells were stained with Annexin V/7-aminoactinomysin (7-AAD) to detect apoptotic cells after 24 or 48 hours. Representative fluorescence-activated cell sorting plots showing detection of Annexin V/7-AAD + cells 24 hours after IM treatment are included. B) Transduced cells (200 cells/group) were pretreated with IM for 24 hours and then plated in colony-forming cell assays. Colony numbers produced in semisolid media were counted and expressed as a percentage of counts obtained from control cells without any drug added. C–E) Control K562 cells, AHI-1 –transduced SH4-bulk K562 cells (with suppressed AHI-1 expression), lenti-AHI-1 K652 cells (overexpressing AHI-1 ) and IM-resistant K562 cells were incubated with IM ( C ), or TG101209 (TG) alone ( D ), or both in combination ( E ), or with no drug for 48 hours and the percentage of viable cells was then measured. F) AHI-1 was immunoprecipitated from cell lysates of AHI-1 –overexpressing K562 cells treated with IM and TG alone or in combination for 16 hours. The immunoprecipitates were then probed with an antityrosine phosphorylation antibody (4G10), a BCR-ABL antibody, a JAK2 antibody, and an AHI-1 antibody. Control cells = Hut78 cells. Data are means, and error bars represent 95% confidence intervals from three independent experiments in triplicate. P values were calculated using a two-sided Student t test. WB = Western blotting.

Article Snippet: The antibodies in this study included a rabbit polyclonal N-terminal AHI-1 antibody and an antimouse Ahi-1 mouse monoclonal antibody (1:1000 dilution) (C-mAhi-1 M5, Applied Biological Materials Inc Vancouver, BC, Canada), an antimouse ABL mouse monoclonal antibody (1:1000 dilution) (8E9; BD Biosciences), an antimouse JAK2 rabbit monoclonal antibody (1:1000 dilution) (Cell signaling Technology, MA), a rabbit polyclonal anti-JAK2 agarose conjugated antibody (Santa Cruz Biotechnology), anti-phospho-JAK2 rabbit polyclonal antibodies (1:1000 dilution) (Cell Signaling and Epitomics Inc, Burlingame, CA), an antihuman STAT5 rabbit polyclonal antibody (1:1000 dilution) (Millipore, Billeria, MA), an anti-phospho-STAT5 rabbit monoclonal antibody (1:1000 dilution) (Cell Signaling), an antihuman phospho-CRKL rabbit polyclonal antibody (1:2000 dilution) (Cell Signaling), an antihuman CRKL rabbit polyclonal antibody (1:1000 dilution) (Santa Cruz Biotechonolgy), an antiphosphotyrosine mouse monoclonal antibody (4G10) (1:2000 dilution) (Millipore, Billerica, MA), an anti-phospho-AKT rabbit polyclonal antibody (1:1000 dilution) (Cell Signaling), an antimouse Akt rabbit polyclonal antibody (1:1000 dilution) (Cell Signaling), an antihuman phospho-ERK rabbit polyclonal antibody (1:1000 dilution), an antirat ERK rabbit polyclonal (1:1000 dilution), an antimouse GAPDH mouse monoclonal antibody (1:2000 dilution) (Sigma Aldrich), an antiactin mouse monoclonal antibody (1:1000 dilution) (Sigma Aldrich), and an anti-HA mouse monoclonal antibody (1:1000 dilution) (Applied Biological Materials Inc).

Techniques: Inhibition, Cell Culture, Staining, Fluorescence, FACS, Produced, Control, Expressing, Incubation, Immunoprecipitation, Phospho-proteomics, Western Blot

Journal: JNCI Journal of the National Cancer Institute

Article Title: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

doi: 10.1093/jnci/djt006

Figure Lengend Snippet: Inhibition of phosphorylation of BCR-ABL, CRK-like (CRKL), Janus kinase 2 (JAK2), and signal transducer and activator of transcription 5 (STAT5) in transduced K562 cells in response to combined treatment with TG101209 (TG) and imatinib (IM). A) K562 cells, Abelson helper integration site 1 ( AHI-1 )–overexpressing K562 cells, and IM-resistant K562 cells (IMR) were cultured with or without IM, TG, or a combination of IM and TG for 16 hours. Western blot analysis detected phosphorylation and protein expression of various proteins using the specific antibodies indicated. B) BV173 cells were treated with IM, TG, or IM plus TG for 16 hours. Cell lysates were immuno-probed with the specific antibodies indicated. GAPDH or actin was utilized as a loading control.

Article Snippet: The antibodies in this study included a rabbit polyclonal N-terminal AHI-1 antibody and an antimouse Ahi-1 mouse monoclonal antibody (1:1000 dilution) (C-mAhi-1 M5, Applied Biological Materials Inc Vancouver, BC, Canada), an antimouse ABL mouse monoclonal antibody (1:1000 dilution) (8E9; BD Biosciences), an antimouse JAK2 rabbit monoclonal antibody (1:1000 dilution) (Cell signaling Technology, MA), a rabbit polyclonal anti-JAK2 agarose conjugated antibody (Santa Cruz Biotechnology), anti-phospho-JAK2 rabbit polyclonal antibodies (1:1000 dilution) (Cell Signaling and Epitomics Inc, Burlingame, CA), an antihuman STAT5 rabbit polyclonal antibody (1:1000 dilution) (Millipore, Billeria, MA), an anti-phospho-STAT5 rabbit monoclonal antibody (1:1000 dilution) (Cell Signaling), an antihuman phospho-CRKL rabbit polyclonal antibody (1:2000 dilution) (Cell Signaling), an antihuman CRKL rabbit polyclonal antibody (1:1000 dilution) (Santa Cruz Biotechonolgy), an antiphosphotyrosine mouse monoclonal antibody (4G10) (1:2000 dilution) (Millipore, Billerica, MA), an anti-phospho-AKT rabbit polyclonal antibody (1:1000 dilution) (Cell Signaling), an antimouse Akt rabbit polyclonal antibody (1:1000 dilution) (Cell Signaling), an antihuman phospho-ERK rabbit polyclonal antibody (1:1000 dilution), an antirat ERK rabbit polyclonal (1:1000 dilution), an antimouse GAPDH mouse monoclonal antibody (1:2000 dilution) (Sigma Aldrich), an antiactin mouse monoclonal antibody (1:1000 dilution) (Sigma Aldrich), and an anti-HA mouse monoclonal antibody (1:1000 dilution) (Applied Biological Materials Inc).

Techniques: Inhibition, Phospho-proteomics, Cell Culture, Western Blot, Expressing, Control

Journal: JNCI Journal of the National Cancer Institute

Article Title: Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

doi: 10.1093/jnci/djt006

Figure Lengend Snippet: Effects of oral administration of TG101209 (TG) and imatinib (IM) on elimination of chronic myeloid leukemia (CML) BV173 cells and survival of leukemic mice in immunodeficient mice. A) BV173 cells were cultured with 1.0 µM IM, 0.5 µM TG, IM plus TG, or no drug for 3 days, and the progeny recovered from 2.5×10 6 initial cells were then injected intravenously into NOD/SCID–interleukin 2 receptor γ–chain-deficient (NSG) mice (n = 6 mice per condition). The left panel shows fluorescence-activated cell sorting profiles of engrafted human CD19/20 + cells detected in bone marrow aspirates of representative mice obtained 3 weeks posttransplant. The percentage of human CD19/20 + BV173 cells detected in the bone marrow of mice examined 3 weeks after injection is shown in the right panel . Data are means, and error bars represent 95% confidence intervals of six measurements per condition. B) Survival curve for recipients of BV173 cells (2.5×10 6 per mouse; n = 6 mice per group) treated by oral gavage beginning at 2 weeks posttransplant with vehicle, IM (50mg/kg), TG (60mg/kg), and IM (50mg/kg) plus TG (60mg/kg) twice a day for 2 weeks. Statistically significantly prolonged survival was observed in mice receiving the combination treatment ( left panel ). Body weights of mice in each treated group were measured, as indicated in the right panel . Log-rank tests were used to compare median survival of different groups (n = 6 mice per group), and P values were calculated using a two-sided Student t test. C) Model of the mechanism by which Abelson helper integration site 1 (AHI-1)–BCR-ABL and AHI-1–Janus kinase 2 (JAK2) interactions regulate constitutive activation of BCR-ABL and JAK2/ signal transducer and activator of transcription 5 (STAT5), resulting in increased leukemic stem cell proliferation, survival and maintenance and reduced tyrosine kinase inhibitor (TKI) response of these cells. Targeting both BCR-ABL and JAK2 activities to destabilize this complex perturbs these biological properties. IL-3 = interleukin 3; IL-3R = interleukin 3 receptor.

Article Snippet: The antibodies in this study included a rabbit polyclonal N-terminal AHI-1 antibody and an antimouse Ahi-1 mouse monoclonal antibody (1:1000 dilution) (C-mAhi-1 M5, Applied Biological Materials Inc Vancouver, BC, Canada), an antimouse ABL mouse monoclonal antibody (1:1000 dilution) (8E9; BD Biosciences), an antimouse JAK2 rabbit monoclonal antibody (1:1000 dilution) (Cell signaling Technology, MA), a rabbit polyclonal anti-JAK2 agarose conjugated antibody (Santa Cruz Biotechnology), anti-phospho-JAK2 rabbit polyclonal antibodies (1:1000 dilution) (Cell Signaling and Epitomics Inc, Burlingame, CA), an antihuman STAT5 rabbit polyclonal antibody (1:1000 dilution) (Millipore, Billeria, MA), an anti-phospho-STAT5 rabbit monoclonal antibody (1:1000 dilution) (Cell Signaling), an antihuman phospho-CRKL rabbit polyclonal antibody (1:2000 dilution) (Cell Signaling), an antihuman CRKL rabbit polyclonal antibody (1:1000 dilution) (Santa Cruz Biotechonolgy), an antiphosphotyrosine mouse monoclonal antibody (4G10) (1:2000 dilution) (Millipore, Billerica, MA), an anti-phospho-AKT rabbit polyclonal antibody (1:1000 dilution) (Cell Signaling), an antimouse Akt rabbit polyclonal antibody (1:1000 dilution) (Cell Signaling), an antihuman phospho-ERK rabbit polyclonal antibody (1:1000 dilution), an antirat ERK rabbit polyclonal (1:1000 dilution), an antimouse GAPDH mouse monoclonal antibody (1:2000 dilution) (Sigma Aldrich), an antiactin mouse monoclonal antibody (1:1000 dilution) (Sigma Aldrich), and an anti-HA mouse monoclonal antibody (1:1000 dilution) (Applied Biological Materials Inc).

Techniques: Cell Culture, Injection, Fluorescence, FACS, Activation Assay

Journal: Oncology reports

Article Title: Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.

doi: 10.3892/or.2017.5588

Figure Lengend Snippet: Figure 2. Silibinin downregulates the expression of Jak2/STAT3 signaling proteins in a dose- and time-dependent manner. (A) Western blot analyses showing the concentration dependent effect of silibinin in MDA‑MB‑231 cells following exposure to silibinin for 24 h. (B) Relative levels of the pSTAT3, STAT3, pJak2, and Jak2 proteins. (C) Time-dependent effect of silibinin on protein expression in MDA‑MB‑231 cells. (D) Relative expression levels of pSTAT3, STAT3, pJak2, and Jak2, measured using densitometry. These data were normalized to actin levels, and then shown as a percentage of the control. The data presented are representative of three independent experiments. Statistical analyses were conducted using the t-test (**p<0.01, ***p<0.001).

Article Snippet: An anti phosphor Jak2 antibody (Tyrosine residue 1007/1008) was purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Expressing, Western Blot, Concentration Assay, Control

Journal: Oncology reports

Article Title: Silibinin downregulates MMP2 expression via Jak2/STAT3 pathway and inhibits the migration and invasive potential in MDA-MB-231 cells.

doi: 10.3892/or.2017.5588

Figure Lengend Snippet: Figure 7. Schematic representation of the inhibition of invasive mechanisms provoked by silibinin in MDA‑MB‑231 cells. Silibinin inhibits Jak2 expression and phosphorylation, resulting, in turn, in the inhibition of STAT3 expression, phosphorylation, nuclear translocation, and DNA binding activity. Consequently, STAT3's down-stream targets are inhibited (including MMP2), resulting in reduced cell migration and invasion.

Article Snippet: An anti phosphor Jak2 antibody (Tyrosine residue 1007/1008) was purchased from Cell Signaling Technology (Beverly, MA, USA).

Techniques: Inhibition, Expressing, Phospho-proteomics, Translocation Assay, Binding Assay, Activity Assay, Migration